BioCryst Pharmaceuticals (FRA:BO1) Cyclically Adjusted PB Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BO1 BioCryst Pharmaceuticals Inc FRA:BO1
65 GF Score
Price €8.33
GF Value €10.62
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCryst Pharmaceuticals  (FRA:BO1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.71 57.70 902.39 0.00 0.00

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:BO1 vs PBH, SUPN, AMLX: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:BO1
65GF Score
BioCryst Pharmaceuticals Inc FRA:BO1
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioCryst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, BioCryst Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.886/330.2130*330.2130
=-1.886

Current CPI (Mar. 2026) = 330.2130.

BioCryst Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.162 241.018 0.222
201609 0.048 241.428 0.066
201612 0.020 241.432 0.027
201703 0.448 243.801 0.607
201706 0.266 244.955 0.359
201709 0.858 246.819 1.148
201712 0.719 246.524 0.963
201803 0.510 249.554 0.675
201806 0.400 251.989 0.524
201809 0.570 252.439 0.746
201812 0.393 251.233 0.517
201903 0.181 254.202 0.235
201906 -0.074 256.143 -0.095
201909 -0.339 256.759 -0.436
201912 0.223 256.974 0.287
202003 0.021 258.115 0.027
202006 0.385 257.797 0.493
202009 0.162 260.280 0.206
202012 -0.090 260.474 -0.114
202103 -0.355 264.877 -0.443
202106 -0.493 271.696 -0.599
202109 -0.695 274.310 -0.837
202112 -0.514 278.802 -0.609
202203 -0.803 287.504 -0.922
202206 -1.085 296.311 -1.209
202209 -1.315 296.808 -1.463
202212 -1.480 296.797 -1.647
202303 -1.623 301.836 -1.776
202306 -1.893 305.109 -2.049
202309 -2.029 307.789 -2.177
202312 -2.030 306.746 -2.185
202403 -2.123 312.332 -2.245
202406 -2.138 314.175 -2.247
202409 -2.038 315.301 -2.134
202412 -2.179 315.605 -2.280
202503 -1.998 319.799 -2.063
202506 -1.741 322.561 -1.782
202509 -1.570 324.800 -1.596
202512 -0.478 324.054 -0.487
202603 -1.886 330.213 -1.886

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioCryst Pharmaceuticals (FRA:BO1) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of €8.33 is trading 21.6% below its estimated GF Value™ of €10.62. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for FRA:BO1:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €10.62 vs. price of €8.33 (21.6% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the FRA:BO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABCRX:Mexico
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
65GF Score

Get the complete analysis for FRA:BO1

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.33
Price
€10.62
GF Value